Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

6114 - Anticancer therapy within the last 30 days of life in a regional cancer centre

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Supportive Care and Symptom Management

Presenters

Mike Nguyen

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

M. Nguyen

Author affiliations

  • Medical Oncology, Goulburn Valley Health, 3630 - Shepparton/AU
More

Resources

Abstract 6114

Background

Anticancer therapy within the last 30 days of life is an important indicator of quality end of life care. The decision to cease treatment is complex with several patient, family and clinician driven factors. Similarly, the development of novel anticancer therapies create opportunities for more treatment options. This is reflected in trends toward more aggressive treatment near the end of life. Other institutions in Australia have reported treatment rates within the last 30 days of life of between 10 - 26%.

Methods

Deaths between 1 January 2015 and 30 June 2018 of patients who attended the oncology department were analysed through a retrospective review of medical records.

Results

122 of 444 deaths (27%) occurred in patients who had received anticancer therapy within the last 30 days of life. The majority (96%) were treated with palliative intent. Palliative care service referral status was low (50%) and tended to be later in those who received treatment within the last 30 days of life. Treatment within the last 30 days of life was associated with other indicators of aggressiveness of care including more emergency presentations, hospitalisations and ICU admissions.

Conclusions

A significant number of patients received anticancer therapy within the last 30 days of life. This emphasises difficulties in disease prognostication, the conflict between treatment cessation and trialling other tempting treatment options and the need for referral to palliative care services.

Clinical trial identification

Legal entity responsible for the study

Goulburn Valley Health.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.